Hepatitis A and hepatitis B both cause liver inflammation, but they differ in nearly every way that matters: how you catch them, how long they last, how dangerous they are, and how they’re treated. The single biggest difference is that hepatitis A is a short-term infection your body clears on its own, while hepatitis B can become a lifelong chronic disease that damages your liver over years.
How Each One Spreads
Hepatitis A spreads through the fecal-oral route. That means you get it by swallowing something contaminated with the virus, typically food or water handled by an infected person, or through close personal or sexual contact. Outbreaks often trace back to a restaurant worker, contaminated produce, or unsanitary water. Travel to countries with limited sanitation is a common risk factor.
Hepatitis B spreads through blood and body fluids. The main routes are unprotected sex, sharing needles, and transmission from mother to baby during birth. It can also spread through sharing razors, toothbrushes, or other items that carry trace amounts of blood. You cannot get hepatitis B from food, water, casual contact, or sharing utensils.
Incubation Period and Early Symptoms
After exposure, hepatitis A typically takes 15 to 50 days to cause symptoms, with an average around 28 days. Hepatitis B has a longer incubation period: an average of 90 days from exposure to the onset of symptoms, with a range of 60 to 150 days. That longer window means people with hepatitis B can unknowingly spread the virus for weeks before they feel sick.
Both infections can cause similar initial symptoms: fatigue, nausea, loss of appetite, abdominal pain, dark urine, and jaundice (yellowing of the skin and eyes). With hepatitis B, adults over 30 are more likely to develop noticeable symptoms during the acute phase, while younger adults and children often have no symptoms at all. Hepatitis A tends to cause symptoms more reliably in adults, though young children often have mild or silent infections.
Short-Term vs. Chronic Infection
This is the most important clinical distinction between the two. Hepatitis A never becomes chronic. Your immune system clears the virus completely, usually within a few weeks to months, and you’re immune for life afterward. Severe complications are rare, though older adults and people with pre-existing liver disease face a small risk of liver failure.
Hepatitis B, on the other hand, can become a lifelong infection. The risk of chronic infection depends heavily on age at the time of exposure. Infants infected at birth have roughly a 90% chance of developing chronic hepatitis B. For adults, the risk is much lower, around 5%, but it’s still significant given the consequences. In the United States, an estimated 14,400 new hepatitis B infections occurred in 2023, compared to about 3,300 new hepatitis A infections.
Long-Term Liver Damage From Hepatitis B
Chronic hepatitis B is a serious condition because the virus slowly damages the liver over years, often without symptoms. The five-year rate of developing cirrhosis (severe scarring of the liver) among untreated chronic hepatitis B patients is 8% to 20%. Once cirrhosis develops, the annual risk of liver cancer is 2% to 5%. These numbers add up over decades, making chronic hepatitis B one of the leading causes of liver cancer worldwide.
Hepatitis A carries no equivalent long-term risk. Once the infection resolves, your liver heals completely and there’s no ongoing damage or cancer risk.
How Each Infection Is Treated
There is no specific medication for either acute hepatitis A or acute hepatitis B. In both cases, treatment during the initial infection is supportive: rest, fluids, adequate nutrition, and avoiding alcohol or anything else that stresses the liver. Most people recover fully without intervention.
The difference shows up in the chronic phase. Since hepatitis A doesn’t become chronic, there’s nothing further to treat. Chronic hepatitis B, however, requires ongoing medical monitoring and often antiviral therapy. Several FDA-approved medications can suppress the virus and slow liver damage, though they typically don’t eliminate the infection entirely. People with chronic hepatitis B need regular liver function tests and cancer screening for the rest of their lives. They’re also advised to get vaccinated against hepatitis A, since a second type of hepatitis layered on top of existing liver damage can be dangerous.
Vaccination and Prevention
Both hepatitis A and hepatitis B are vaccine-preventable, and widespread vaccination has dramatically reduced infection rates over the past few decades.
The hepatitis B vaccine is recommended for all infants at birth, all unvaccinated children under 19, and all adults aged 19 to 59. Adults 60 and older with risk factors should also be vaccinated. Depending on the specific vaccine product, the series requires either two or three doses. A combination vaccine that covers both hepatitis A and hepatitis B is also available for adults.
The hepatitis A vaccine is similarly recommended for all children starting at age one, as well as for travelers to high-risk areas, people with chronic liver disease, and others at increased risk. The standard series is two doses given six months apart.
If you’re unsure whether you’ve been vaccinated for either virus, a simple blood test can check for immunity. For hepatitis B specifically, the CDC now recommends a triple-panel blood test that checks three markers at once: a surface protein that indicates active infection, an antibody that shows whether you’re immune from vaccination, and a core antibody that reveals whether you’ve ever been exposed to the virus. This single test can tell you if you’re protected, currently infected, or have had a past infection.
Quick Comparison
- Virus type: Hepatitis A is caused by HAV, hepatitis B by HBV. They are completely different viruses.
- Transmission: HAV spreads through contaminated food and water. HBV spreads through blood and body fluids.
- Incubation: HAV averages about 28 days. HBV averages about 90 days.
- Chronicity: HAV always resolves on its own. HBV can become a lifelong infection.
- Liver cancer risk: None with HAV. Significant with chronic HBV.
- Treatment: Supportive care for both acutely. Chronic HBV requires antiviral therapy and long-term monitoring.
- Prevention: Effective vaccines exist for both, and a combination vaccine covers both in a single series.